- Home
- OSUR vs SKYE Comparison
OSUR vs SKYE Comparison
Compare OSUR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- SKYE
- Stock Information
- Founded
- OSUR 2000
- SKYE 2012
- Country
- OSUR United States
- SKYE United States
- Employees
- OSUR N/A
- SKYE N/A
- Industry
- OSUR Medical/Dental Instruments
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- SKYE Health Care
- Exchange
- OSUR Nasdaq
- SKYE Nasdaq
- Market Cap
- OSUR 223.0M
- SKYE 73.4M
- IPO Year
- OSUR 1986
- SKYE N/A
- Fundamental
- Price
- OSUR $3.08
- SKYE $4.61
- Analyst Decision
- OSUR Hold
- SKYE Buy
- Analyst Count
- OSUR 1
- SKYE 6
- Target Price
- OSUR $3.00
- SKYE $16.60
- AVG Volume (30 Days)
- OSUR 779.0K
- SKYE 2.0M
- Earning Date
- OSUR 08-05-2025
- SKYE 08-08-2025
- Dividend Yield
- OSUR N/A
- SKYE N/A
- EPS Growth
- OSUR N/A
- SKYE N/A
- EPS
- OSUR N/A
- SKYE N/A
- Revenue
- OSUR $161,626,000.00
- SKYE N/A
- Revenue This Year
- OSUR N/A
- SKYE N/A
- Revenue Next Year
- OSUR $6.20
- SKYE N/A
- P/E Ratio
- OSUR N/A
- SKYE N/A
- Revenue Growth
- OSUR N/A
- SKYE N/A
- 52 Week Low
- OSUR $2.36
- SKYE $1.14
- 52 Week High
- OSUR $4.92
- SKYE $7.60
- Technical
- Relative Strength Index (RSI)
- OSUR 60.74
- SKYE 74.70
- Support Level
- OSUR $2.92
- SKYE $3.41
- Resistance Level
- OSUR $3.08
- SKYE $5.75
- Average True Range (ATR)
- OSUR 0.14
- SKYE 0.60
- MACD
- OSUR 0.01
- SKYE 0.17
- Stochastic Oscillator
- OSUR 98.55
- SKYE 69.27
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.